Obstructive Laryngitis Treatment Market Size & Share, by Medication (Glucocorticoid, Dexamethasone, Epinephrine); Drug Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3164
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Obstructive Laryngitis Treatment Market size is expected to reach USD 3.6 Billion by the end of 2036, growing at a CAGR of 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the obstructive laryngitis treatment was over USD 2 Billion. The increasing prevalence of laryngeal disorders, such as vocal cord paralysis, vocal fold lesions, and laryngeal cancers, is a significant growth driver for the market. As per recent estimates, 12,380 new instances of laryngeal cancer are estimated, with 2,480 women and 9,900 males affected. On the other hand, factors like aging populations, changing lifestyles, and environmental factors contribute to the surge in these conditions. As the incidence of such disorders rises, the demand for effective treatment options, driving market growth, becomes more pronounced, shaping the landscape for laryngeal treatments.

As Awareness Grows and diagnostics Capabilities improve, there’s a heightened need for advanced therapeutic solutions, propelling market expansion for obstructive laryngitis treatments.

Obstructive Laryngitis Treatment Market
Get more information on this report: Request Free Sample PDF

Obstructive Laryngitis Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Aging Population & Demand for Advanced Treatments - With an aging demographic prone to laryngeal ailments, the demand for innovative treatments rises. Older individuals are more susceptible to conditions affecting the larynx, necessitating specialized interventions. This demographic trend amplifies the market’s need for tailored obstructive larynx treatments catering to elderly patients’ specific requirements.
  • Minimally Invasive Surgical Techniques- The shift towards minimally invasive procedures in laryngeal treatments offers benefits like reduced recovery time and fewer complications acting as a surgical boom. Growing patient preference for these less invasive approaches drives market growth, pushing healthcare providers and manufacturers to develop and adopt minimally invasive obstructive larynx treatments.
  • Patient-Centric Approach & Personalized Medicine - The shift towards patient-centric care and personalized medicine leads to tailored treatment plans. Customized solutions in obstructive larynx treatments, aligned with individual patient needs, foster market growth as demand increases for specialized and effective therapies designed for specific conditions and patient profiles. According to data from the Personalized Medicine Coalition (PMC), the number of customized medications available in the US increased by over 100% between 2016 and 2020. This provided a major positive impact on the obstructive laryngitis treatment market.


  • Complexity of Laryngeal Disorders- Treating obstructive larynx conditions, including cancer, stenosis, and paralysis, presents challenges due to the intricate anatomy and functions of the larynx. The complexity of these disorders requires tailored approaches, often involving multidisciplinary teams, specialized equipment, and expertise, making treatment planning and execution more intricate.
  • Limited awareness about early detection.
  • Post-treatment complications & rehabilitation.

Obstructive Laryngitis Treatment Market: Key Insights

Base Year


Forecast Year



~ 5%

Base Year Market Size (2023)

~ USD 2 Billion

Forecast Year Market Size (2036)

~ USD 3.6 Billion

Regional Scope


  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Obstructive Laryngitis Treatment Segmentation

 Medication (Glucocorticoid, Dexamethasone, Epinephrine)

The glucocorticoid segment is estimated to hold 52% share of the global obstructive laryngitis treatment market by 2036. Systemic corticosteroid reduces laryngeal edema by reducing local inflammatory responses, contracting lymphocyte inflammation, and limiting capillary permeability. They were one of the main pillars of treatment in patients with croup due to their potent anti-inflammatory effect. It is believed that the anti-inflammatory qualities of glucocorticoids lessen edema and inflammation, which requires less effort from the youngster when breathing. A 2018 Cochrane Review that was updated found that glucocorticoids (prednisone, dexamethasone) shortened hospital stays, decreased the frequency of patient care follow-up visits, and alleviated croup symptoms in two hours. Within six hours of delivery, glucocorticoids were found to lessen the symptoms of croup, according to the earlier version of the Cochrane Review. Research has demonstrated that administering a single dosage of dexamethasone during the initial 4-24 hours post-illness start can lessen the overall severity of croup.

Drug Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

The hospital pharmacy segment in the obstructive laryngitis treatment market is anticipated to hold a significant revenue during the forecast period. The rise in the construction of hospitals backed by increased healthcare expenditure propels the segment’s demand. Further, the wide stock of drugs, therapies, and medical procedures provided by the hospitals is expected to increase the segment’s demand in the upcoming years.

Our in-depth analysis of the global market includes the following segments:


  • Glucocorticoid
  • Dexamethasone
  • Epinephrine

          Drug Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Obstructive Laryngitis Treatment Industry - Regional Synopsis

North American Market Forecast

North American region obstructive laryngitis treatment market is expected to hold 45% of the revenue share by 2036. In the region, the market demonstrates a robust landscape driven by several influential factors. Technological advancements in medical procedures and equipment propel the market’s growth, offering innovative solutions such as laser surgeries, endoscopic interventions, and robotic-assisted treatments. This region’s healthcare infrastructure, coupled with a strong emphasis on research and development, fosters the adoption of cutting-edge therapies for laryngeal disorders. The increasing prevalence of conditions like laryngeal cancer and vocal cord paralysis fuels the demand for effective treatments. Moreover, a growing aging population susceptible to laryngeal ailments contributes to the market expansion.

Asia Pacific Market Statistics

Asia Pacific Market for obstructive laryngitis treatment is estimated to hold significant market value. The region showcases dynamic growth prospects driven by several key factors. The region’s burgeoning population, coupled with lifestyle changes, contributes to an increasing incidence of laryngeal disorders. Advancements in healthcare infrastructure and the adoption of cutting-edge technologies, especially in countries like Japan, South Korea, China, and India, propel the market forward. Rising healthcare expenditure and a growing focus on research and development activities for innovative treatment modalities further augment market expansion.

Research Nester
Obstructive Laryngitis Treatment Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Obstructive Laryngitis Treatment Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • GlaxoSmithKline plc
    • Reckitt Benckiser Group PLC 
    • Sun Pharmaceutical Industries Ltd. 
    • Bayer AG
    • AstraZeneca
    • Novartis Pharmaceuticals Corporation
    • Walgreen Co. 
    • Prestige Consumer Healthcare Inc. 
    • Perrigo Company plc

In the News

  • October, 2022-Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC® ODT (rimegepant), an inventive migraine treatment authorized for the acute treatment as well as the prevention of episodic migraine in adults, was acquired by Pfizer Inc., it was reported.
  • July 2020 - The FDA in the United States has authorized AstraZeneca's Breztri Aerosphere as a maintenance medication for patients with chronic obstructive pulmonary disease (COPD).
  • Breztri Aerosphere, formerly known as PT010, is an inhalation medication that contains three active ingredients: the corticosteroid budesonide, the long-acting beta-2 agonist formoterol fumarate, and the long-acting muscarinic antagonist glycopyrronium.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3164
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Prevalence of laryngitis disorders, minimally invasive surgical techniques, patient-centric, and adoption of personalized medicine are some of the major growth drivers for the obstructive laryngitis treatment market.

The market size of obstructive laryngitis treatment is anticipated to attain a CAGR of 5 % over the forecast period, i.e., 2024-2036.

The major players in the market are GlaxoSmithKline plc, Reckitt Benckiser Group PLC, Sun Pharmaceutical Industries Ltd., Bayer AG, AstraZeneca, Novartis Pharmaceuticals Corporation, Walgreen Co., Prestige Consumer Healthcare Inc., Perrigo Company plc, TAIHO PHARMACEUTICAL CO., LTD. and others.

The glucocorticoid segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Obstructive Laryngitis Treatment Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying